A rapidly growing number of oral anticancer agents has become available in oncology and hematology. Though these introductions have several benefits, medication adherence is an issue concern. Little known about the factors influencing to treatment with daily practice. Material methods. In this observational, multicenter study including 216 patients, carried out between October 2010 March 2012, use drugs was assessed by means a telephonic pill count, questionnaire review patient's medical...

Healthcare provider (HCP) activities and attitudes towards patients strongly influence medication adherence. The aim of this study was to assess current clinical practices support in adhering treatment with oral anticancer agents (OACA) explore clues improve the management A cross-sectional, observational among HCPs (haemato-)oncology settings Belgium Netherlands conducted 2014 using a composite questionnaire. total 47 care were listed categorised into eight domains. also asked about their...

Erlotinib is an orally administered tyrosine kinase inhibitor used for treatment of non-small cell lung cancer. Understanding actual use medication essential optimizing conditions. In this multicentre prospective observational study, patients starting erlotinib were followed 4 months. Adherence was assessed using a event monitoring system (MEMS). Area under the curve (AUC) determined after 1, 2 and Before start at monthly intervals, filled out questionnaires about attitude towards disease,...

Background Cardiovascular medications have well-established benefits in the primary and secondary prevention of cardiovascular diseases. Unfortunately, adherence to these medicines is often suboptimal. To develop interventions intended enhance medications, more insight needed into complex character medication nonadherence. Objective The aim present study was identify which factors are associated with nonadherence a sample patients from Dutch community pharmacies. Methods In this...

Abstract Objectives To compare nilotinib concentrations obtained by venous blood sampling and dried spot (DBS) in patients with chronic myeloid leukaemia (CML). It was investigated how to predict plasma levels on the basis of DBS. Methods Forty duplicate DBS samples were collected from 20 patients. Capillary finger prick spotted DMPK-C Whatman paper, simultaneously sampling. Plasma predicted using three methods: (1) individual (2) mean haematocrit correction (3) bias between concentrations....

Abstract Adequate information on oral anticancer agent (OACA) use is an essential element of optimal cancer care. The present study aimed to get insight into the experiences patients with OACA treatment and their characteristics regarding dissatisfaction. Patients four Dutch university hospitals using participated in this observational completed Satisfaction Information about Medicines Scale (SIMS), EORTC Quality Life Questionnaire‐C30, Brief Illness Perception Questionnaire, Beliefs...

To obtain insight into the feasibility of, and patients' perspective on, dried blood spot (DBS) self-sampling by patients with chronic myeloid leukemia (CML) using nilotinib. Sixty-eight CML nilotinib participated in this multicenter observational study. Patients were asked to perform sampling means of DBS method at home just before drug intake (trough level) complete a questionnaire including demographics five questions on their experience self-sampling. Sixty-one (57.5 ± 15.0 years, 49%...

Introduction: Capecitabine is a widely prescribed oral anticancer agent. We studied medication adherence and explored its use in daily practice from patients' perspective. Patients Methods: (n = 92) starting capecitabine were followed up to five 3-week cycles. Adherence was assessed using pill count, pharmacy data dosing information the medical file. Self-reported measured Medication Report Scale (MARS). At baseline during week 2 of cycles 1, 3, 5, patients filled out questionnaires about...

To obtain insight into patients' reasons for medication (non)adherence in chronic myeloid leukaemia (CML) and needs wishes regarding information communication.

Introduction Non-adherence to medication is a complex health care problem. In spite of substantial efforts, up till now little progress has been made effectively tackle the problem with adherence-enhancing interventions. The aim this study was investigate effectiveness patient-tailored, pharmacist-led and theory-driven intervention program aimed enhance self-reported adherence antihypertensive medication. Materials methods A parallel-group randomized controlled trial in 20 community...

Introduction Hypertension is considered an important public health issue. Inadequate disease management and non-adherence to antihypertensive medication may result in suboptimal clinical outcomes thereby imposing a financial burden on society. This study evaluates the cost-effectiveness of patient-tailored, pharmacist-led intervention program aimed enhance adherence comparison with usual care. Materials methods An economic evaluation was conducted alongside pragmatic randomized controlled...

Abstract Background Adherence to pharmacological therapy is a complex and multi-factorial issue that can substantially alter the outcome of treatment. It has been shown cancer patients, especially when using long-term medication, have similar adherence rates those patients with other diseases. The consequences poor are health outcomes increased care costs. Only few studies focused on use oral anticancer agents in daily practice. Information about reasons for non-adherence essential...

Background The management of multiple long-term medicines patients with chronic diseases creates a burden for patients. However, limited research is performed on its impact patients' daily lives. Objective aim this study was to explore the cardiovascular medication different life aspects and examine differences these between adherent non-adherent Setting Two community pharmacies in Netherlands. Method In cross-sectional (≥ 45 years) using participated. equally group sized samples as assessed...

Background Insight into the delivery of interventions is necessary to gain a better understanding what caused an intervention succeed or fail. The Cardiovascular medication non-Adherence Tailored Intervention (CATI) study failed show effectiveness patient-tailored, pharmacist-led programme on self-reported adherence antihypertensive medication. Objective To evaluate implementation fidelity CATI programme. Setting Twenty Dutch community pharmacies. Method process randomised controlled trial...

Background Little is known about healthcare providers' (HCPs) perceptions of adherence management oral anticancer agents (OACA). The study aims to explore HCPs OACA and adherence.Methods A cross-sectional, multi-center observational among in hemato-oncology settings Belgium the Netherlands was conducted. Physicians, nurse practitioners, nurses pharmacists were asked complete questionnaires on their perception patient its (PAMQ) beliefs (BMQ-Specific). Physicians also a questionnaire shared...

Medication non-adherence is a complex health care problem. Due to non-adherence, substantial numbers of cardiovascular patients benefit from their medication only limited extent. In order improve adherence, variety pharmacist-led interventions have been developed. However, even the most effective achieved modest positive effect. To be effective, should targeted at underlying barriers developed in systematic manner and tailored specific features target group setting. The current paper...

Abstract Introduction This comprehensive observational study aimed to gain insight into adherence nilotinib and the effect of (non)adherence on exposure ( C min ) treatment outcomes. Methods Chronic myeloid leukemia (CML) patients using were followed for 12 months. Adherence was measured by Medication Event Monitoring System (MEMS), pill count, Report Scale (MARS-5). Nilotinib patient-reported outcomes (i.e., quality life, side effects, beliefs, satisfaction) at baseline, 3, 6, Results...

Taking advantage of its food-dependent bioavailability, the present study investigated effect a reduced dose taken with real-life meals on pharmacokinetics (PK) nilotinib in chronic myeloid leukaemia (CML) patients.Nilotinib was fasted (300 mg BID, days 1-4) or (200 5-11). Rich sampling (days 1, 3, 8, 11) allowed for non-compartmental PK analysis. Nilotinib exposure (AUC0-12 h -Cmin -Cmax ) and intra- interpatient variability were compared between two regimens. Adverse events recorded by...

The antitumor drug nilotinib has a large inter- and intra individual variability in pharmacokinetics. Adherence to treatment may substantially influence plasma levels been recognized as the most important determinant of failure chronic myeloid leukemia (CML). A better understanding various factors contributing efficacy is essential for development interventions optimize phase CML (CP-CML) with protein kinase inhibitor like nilotinib.In this multicenter prospective observational cohort study...

Patients with chronic myeloid leukemia (CML) in deep molecular remission may discontinue tyrosine kinase inhibitor (TKI) treatment without relapse. The present study aims to gain insight into the views of CML patients on TKI discontinuation and identify factors that are associated their willingness treatment. A cross-sectional study, among adult Dutch was conducted assess benefits concerns about discontinuation. total 185 participated whom 76% were willing TKI-treatment. considered absence...

<b><i>Background:</i></b> The present study was designed to obtain insights into guideline adherence regarding the use of expensive drugs in Netherlands daily practice and patients' perspective on decision-making process. <b><i>Material Methods:</i></b> A retrospective review medical charts trastuzumab early metastatic breast cancer (EBC/MBC) bortezomib multiple myeloma (MM) conducted. Prescription according clinical guidelines assessed....